• Joeli A Brinkman, Steven C Fausch, Jeffrey S Weber, and W Martin Kast.
• University of Southern California, 1501 San Pablo Street, ZNI 245, MC 2821, Los Angeles, CA 90089-2821, USA.
• Expert Opin Biol Ther. 2004 Feb 1;4(2):181-98.

AbstractOne approach in the immunotherapy of cancer patients involves vaccination with peptides derived from tumour-associated antigens specifically designed to associate with T cells in the context of major histocompatibility complex (MHC) class I or II molecules. Several clinical trials in different tumour types have been conducted utilising this vaccination strategy. The majority of trials indicate that peptide vaccination has few toxicities associated with its administration, but disparities exist between in vitro and clinical responses. However, this represents an evolving field and, thus, it is difficult to draw firm conclusions concerning the efficacy of peptide-based vaccines for cancer immunotherapy. Improvements to peptide vaccination, including the addition of various adjuvants, the utilisation of peptide-pulsed dendritic cells, multipeptide vaccinations, the addition of helper peptides and peptide delivery through the use of mini-genes, are encouraging and serve as important guides for future research.

30 keywords...

hide…